AZoLifeSciences on MSN1mon
High-throughput screening identifies potential drugs for low-grade serous ovarian cancerThese included the mitogen-activated protein kinase kinase (MAP2K)/ mitogen-activated protein kinase kinase kinase (MAP3K)/ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback